Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary
BackgroundRenal cell carcinoma (RCC) is a prevalent tumor of the urinary system. Beyond surgical treatment, targeted therapies and immunotherapies are the primary therapeutic options for RCC. Although immunotherapy has been extensively studied, researc…